Keratoacanthoma and Cutaneous Squamous Cell Carcinoma With PD-1 and PD-L1 Inhibitor Use

JAMA Dermatol. 2024 May 1;160(5):573-575. doi: 10.1001/jamadermatol.2024.0390.
No abstract available

Plain language summary

This cross-sectional study assesses risk of dermatological immune-related adverse events associated with immunotherapy for cancer.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • B7-H1 Antigen / antagonists & inhibitors
  • Carcinoma, Squamous Cell* / drug therapy
  • Carcinoma, Squamous Cell* / pathology
  • Female
  • Humans
  • Immune Checkpoint Inhibitors* / adverse effects
  • Immune Checkpoint Inhibitors* / therapeutic use
  • Keratoacanthoma* / diagnosis
  • Keratoacanthoma* / drug therapy
  • Keratoacanthoma* / pathology
  • Male
  • Middle Aged
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Skin Neoplasms* / diagnosis
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / pathology